intrexon

@Intrexon

We are a community of scientists and creative innovators working to build a safer, healthier planet, and a more promising future. (NASDAQ: )

Vrijeme pridruživanja: travanj 2014.

Tweetovi

Blokirali ste korisnika/cu @Intrexon

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Intrexon

  1. prije 7 minuta

    completes series of transactions to solidify healthcare focus. Name changes to from and ticker symbol to :

    Poništi
  2. 15. sij

    Triple-Gene to highlight its investigational in Phase 1 for treatment of at TODAY January 15th at 11:30am PT in Franciscan B at the Hilton San Francisco Union Square

    Poništi
  3. 14. sij

    At ? Listen to Dr. Helen Sabzevari, President & CEO of , at 5pm PT in California West present on progress and 2020 look ahead OR watch live webcast here:

    Poništi
  4. proslijedio/la je Tweet
    13. sij

    Join Dr. Helen Sabzevari, President and CEO of Precigen, at for her presentation on Precigen’s progress and a 2020 look ahead.

    Poništi
  5. 9. sij

    Triple-Gene to highlight advantages of its multigenic approach for treatment of at on January 15th, 2020 at 11:30AM PT at the Hilton San Francisco Union Square. Read more here:

    Poništi
  6. proslijedio/la je Tweet
    7. sij

    Just four days after Germantown's Intrexon Corp. made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment.

    Poništi
  7. proslijedio/la je Tweet
    6. sij

    receives first regulatory designation for PRGN-3006 UltraCAR-T

    Poništi
  8. 2. sij

    To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To To Reflect Healthcare Focus. Read more here:

    Poništi
  9. proslijedio/la je Tweet
    19. stu 2019.

    ’s Tim Chan to present preclinical data from PRGN-3006 UltraCAR-T at in Orlando, FL

    Poništi
  10. proslijedio/la je Tweet
    2. pro 2019.

    Dr. Helen Sabzevari, President of , will speak at the upcoming World Vaccine & Immunotherapy Congress in San Francisco. Join us! -T

    Poništi
  11. proslijedio/la je Tweet
    2. pro 2019.

    Great news from our partners at ! Enrollment is now complete for their phase 2 clinical trial of AG013 for . AG013 is an ActoBio Therapeutics Inc. candidate created on our ® platform and licensed to Oragenics. More:

    Poništi
  12. 18. stu 2019.

    subsidiary Triple-Gene presented preliminary phase 1 trial data of investigational multigenic therapeutic candidate INXN 4001 for treatment of at . Discover more: and

    Poništi
  13. 15. stu 2019.

    Discover more about Triple-Gene’s approach to address : highlights “The Heart of the Matter: Leveraging Advances in Cardiac Biology to Innovate Gene-Based Therapies for Heart Failure”

    Poništi
  14. 12. stu 2019.

    Intrexon Reports Third Quarter Financial Results: . to host conference call today at 11am ET to provide Precigen business and pipeline updates. Register for call here:

    Poništi
  15. 7. stu 2019.

    Intrexon subsidiary Triple-Gene announces completion of dosing in Phase 1 trial of INXN-4001, first multigenic investigational candidate for treatment of . Learn more here:

    Poništi
  16. 4. stu 2019.

    to Announce Third Quarter Financial Results on Nov 12th. to host conference call that day at 11am ET to provide Precigen business and pipeline updates. To learn more and register, click here:

    Poništi
  17. proslijedio/la je Tweet
    Poništi
  18. 23. lis 2019.

    At ? Don’t miss Therapeutics™ CEO Pieter Rottiers presenting an overview of the innovative ActoBiotics® platform today Wednesday October 23 @ 9:15 AM PT. Read more: or follow us on LinkedIn or Twitter

    Poništi
  19. 1. lis 2019.

    At ? Don't miss Therapeutics™ CEO Pieter Rottiers' presentation at 4PM today about the innovative ActoBiotics® platform. More: or follow on Twitter or LinkedIn.

    Poništi
  20. 26. ruj 2019.

    David Witte formerly of to lead MBP Titan LLC, standalone subsidiary company of Intrexon comprising Intrexon’s Platform. Discover more: .

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·